INVO Fertility (NASDAQ:IVF) Upgraded to “Strong-Buy” at Maxim Group

Maxim Group upgraded shares of INVO Fertility (NASDAQ:IVF) from a hold rating to a strong-buy rating in a report issued on Tuesday morning,Zacks.com reports.

INVO Fertility Stock Up 0.5%

Shares of NASDAQ IVF opened at $1.11 on Tuesday. INVO Fertility has a twelve month low of $0.71 and a twelve month high of $123.52. The firm has a market cap of $2.65 million, a PE ratio of 0.00 and a beta of 2.65. The business has a fifty day simple moving average of $1.16 and a two-hundred day simple moving average of $5.19.

Institutional Investors Weigh In On INVO Fertility

A hedge fund recently bought a new stake in INVO Fertility stock. Citadel Advisors LLC bought a new stake in INVO Fertility, Inc (NASDAQ:IVF) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 66,849 shares of the company’s stock, valued at approximately $51,000. Citadel Advisors LLC owned about 1.19% of INVO Fertility at the end of the most recent reporting period. Hedge funds and other institutional investors own 12.02% of the company’s stock.

INVO Fertility Company Profile

INVO Fertility (NASDAQ:IVF) is a medical technology company focused on advancing assisted reproductive treatments through innovative in-vivo incubation solutions. The company develops and commercializes devices designed to facilitate fertilization and early embryo development inside a patient’s body, offering an alternative to conventional laboratory-based in vitro fertilization (IVF) techniques.

The company’s flagship product, the INVOcell device, is a single-use, intravaginal incubator that holds a controlled microenvironment for egg and sperm co-incubation.